Walleye Capital
GPCR icon

Walleye Capital’s Structure Therapeutics GPCR Stock Holding History

Walleye Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,600
Closed -$366K – 4898
2026
Q1 		$366K Sell
7,600
-300
-4% -$20.5K ﹤0.01% 2905
2025
Q4 		$549K Sell
7,900
-300
-4% -$12.2K ﹤0.01% 2902
2025
Q3 		$230K Buy
8,200
+6,800
+486% +$135K ﹤0.01% 3228
2025
Q2 		$29K Buy
+1,400
New +$30.8K ﹤0.01% 4178
2025
Q1 		– Sell
-600
Closed -$16.3K – 4574
2024
Q4 		$16.3K Buy
+600
New +$21.3K ﹤0.01% 4530
2024
Q3 		– Sell
-1,600
Closed -$62.8K – 5496
2024
Q2 		$62.8K Sell
1,600
-300
-16% -$12.3K ﹤0.01% 4870
2024
Q1 		$81.4K Buy
+1,900
New +$80.1K ﹤0.01% 4494

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Walleye Capital's GPCR Position: Q2 2026 in Review

Walleye Capital sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 21,360 shares — an estimated $1.03M sold.

Walleye Capital first reported a position in GPCR in Q1 2024 and held it in 7 quarters. The position peaked at $4.02M in Q1 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Walleye Capital reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 21,360 Structure Therapeutics shares in Q2 2026, an estimated $1.03M.
  • Walleye Capital first reported a position in Structure Therapeutics in Q1 2024 and held it in 7 quarters.
  • Walleye Capital's Structure Therapeutics position peaked at $4.02M in Q1 2024.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.